Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Jun-30-23 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues: |
| General Surgery | 176.9 | 157.0 | 134.8 | 156.4 | 143.1 | 147.3 | 125.5 | 140.1 |
| Orthopedic Surgery | 140.8 | 120.2 | 107.5 | 117.6 | 105.8 | 107.9 | 107.2 | 112.8 |
| Total revenues | 317.7 | 277.2 | 242.3 | 274.0 | 248.8 | 255.2 | 232.7 | 252.8 |
| Revenue growth [+] | 14.6% | 8.6% | 4.1% | 8.4% | 4.6% | 61.7% | 8.7% | -4.5% |
| General Surgery | 12.6% | 6.6% | 7.4% | 11.6% | 5.5% | 51.4% | 9.4% | -0.7% |
| Orthopedic Surgery | 17.1% | 11.4% | 0.3% | 4.3% | 3.5% | 78.4% | 7.9% | -8.9% |
| Cost of goods sold | 147.0 | 125.4 | 106.3 | 118.1 | 106.5 | 113.7 | 104.2 | 117.3 |
| Gross profit | 170.7 | 151.8 | 136.0 | 155.9 | 142.3 | 141.4 | 128.4 | 135.5 |
| Gross margin | 53.7% | 54.8% | 56.1% | 56.9% | 57.2% | 55.4% | 55.2% | 53.6% |
| Selling, general and administrative [+] | 129.7 | 115.8 | 102.9 | 107.3 | 104.7 | 104.4 | 98.3 | 99.1 |
| General and administrative | | | | 107.3 | | | | 99.1 |
| Research and development | 13.6 | 11.5 | 10.7 | 11.4 | 10.9 | 11.3 | 10.0 | 11.7 |
| EBITDA [+] | | 41.8 | 39.3 | 54.7 | 43.9 | 43.5 | 38.4 | 42.7 |
| EBITDA growth | -34.4% | -3.9% | 2.4% | 28.0% | -7.2% | -209.6% | 21.4% | -9.3% |
| EBITDA margin | 8.6% | 15.1% | 16.2% | 20.0% | 17.7% | 17.0% | 16.5% | 16.9% |
| Depreciation | -8.8 | 4.1 | 8.8 | 9.1 | 3.8 | 4.0 | 10.0 | 9.4 |
| EBITA | 36.2 | 37.7 | 30.4 | 45.6 | 40.1 | 39.5 | 28.4 | 33.3 |
| EBITA margin | 11.4% | 13.6% | 12.6% | 16.6% | 16.1% | 15.5% | 12.2% | 13.2% |
| Amortization of intangibles | 8.8 | 13.3 | 8.0 | 8.4 | 13.4 | 13.8 | 8.3 | 8.6 |
| EBIT [+] | 27.4 | 24.5 | 22.4 | 37.2 | 26.7 | 25.7 | 20.1 | 24.7 |
| EBIT growth | 12.1% | -4.9% | 11.8% | 50.7% | -9.1% | -221.0% | 52.5% | -11.4% |
| EBIT margin | 8.6% | 8.8% | 9.3% | 13.6% | 10.7% | 10.1% | 8.6% | 9.8% |
| Interest expense | 10.0 | 5.9 | 5.0 | 7.6 | 8.1 | 9.4 | 10.4 | 11.1 |
| Interest expense | 10.0 | 5.9 | 5.0 | 7.6 | 8.1 | 9.4 | 10.4 | 11.1 |
| Other income (expense), net [+] | | -112.0 | | | -1.1 | | | -0.1 |
| Other non-ooperating expenses | | 112.0 | | | 1.1 | | | 0.1 |
| Other | | -112.0 | | | -1.1 | | | -0.1 |
| Pre-tax income | 17.4 | -93.5 | 17.4 | 29.6 | 17.4 | 16.3 | 9.7 | 13.5 |
| Income taxes | 3.7 | 74.8 | 2.5 | 5.2 | 2.5 | 3.0 | -0.1 | -10.6 |
| Tax rate | 21.2% | | 14.2% | 17.6% | 14.3% | 18.4% | | |
| Net income | 13.7 | -168.3 | 15.0 | 24.4 | 14.9 | 13.3 | 9.9 | 24.1 |
| Net margin | 4.3% | -60.7% | 6.2% | 8.9% | 6.0% | 5.2% | 4.2% | 9.5% |
| |
| Basic EPS [+] | $0.45 | ($5.65) | $0.51 | $0.84 | $0.51 | $0.46 | $0.34 | $0.84 |
| Growth | -107.9% | -1338.7% | 49.5% | -0.8% | 113.8% | -147.5% | | 60.2% |
| Diluted EPS [+] | $0.43 | ($5.65) | $0.43 | $0.76 | $0.47 | $0.41 | $0.31 | $0.82 |
| Growth | -107.6% | -1480.7% | 35.6% | -7.4% | 99.8% | -142.6% | | 61.8% |
| |
| Dividends per share [+] | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 |
| Growth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -0.1% |
| |
| Shares outstanding (basic) [+] | 30.7 | 29.8 | 29.4 | 29.2 | 29.2 | 29.1 | 29.0 | 28.6 |
| Growth | 3.0% | 2.2% | 1.6% | 2.0% | 2.1% | 2.0% | 1.7% | 0.9% |
| Shares outstanding (diluted) [+] | 31.8 | 29.8 | 35.2 | 32.2 | 32.1 | 32.5 | 31.4 | 29.5 |
| Growth | 6.8% | -8.3% | 12.0% | 9.3% | 9.2% | 13.7% | 5.6% | -0.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|